NCT06454110View on ClinicalTrials.gov

Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

July 31, 2027

Conditions

IgA Nephropathy

Interventions

DRUG

NM8074

NM8074 will be administered as an intravenous infusion. All subjects will be administered 17 mg/kg of NM8074 intravenously weekly for a total of 15 doses from Day 1 to Day 99 of the Treatment Period.